Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698
A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis
Sponsor: GlaxoSmithKline
Terminated
Change in benefit/risk profile
A PHASE2 clinical study on Amyloidosis, this trial is terminated or withdrawn. The trial is conducted by GlaxoSmithKline and has accumulated 13 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
May 2019 — Nov 2019 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
▶ Show 8 earlier versions
-
Sep 2018 — May 2019 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .